OCS OCULIS HOLDING AG

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended.

Attachments



EN
20/03/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Co...

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update ZUG, Switzerland, March 03, 2026 (GLOBE NEWSWIRE) -- Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2 2026 Key expansion in neuro-ophthalmology with Breakthrough Therapy designation granted to Privosegtor, propelling the PIONEER registrational program in optic neuropathies with a potential U.S. market opportunity o...

2h / 23m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2025 og kynnir ...

Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2025 og kynnir áfanga í rekstri félagsins ZUG, Sviss, March 03, 2026 (GLOBE NEWSWIRE) -- Árið 2025 náðist mikilvægur árangur, sem gerir Oculis kleift að ná ýmsum klínískum áföngum í rannsóknum á síðari stigum. Þar er fyrst um að ræða væntanlegar fyrstu niðurstöður (e. topline results) úr DIAMOND fasa 3 rannsóknum á OCS-01 augndropum við sjónhimnubjúg af völdum sykursýki (e. diabetic macular edema, DME) á öðrum ársfjórðungi 2026 Privosegtor hlaut stöðu byltingarkennds meðferðarlyfs sem styrkir PIONEER skráningarrannsóknaráætlunina á sj...

2h / 23m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Co...

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2 2026 Key expansion in neuro-ophthalmology with Breakthrough Therapy designation granted to Privosegtor, propelling the PIONEER registrational program in optic neuropathies with a potential U.S. market opportunity of over $7 billion Cash, cash equivalents, and short-ter...

2h / 23m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment

February 27, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated ZUG, Switzerland, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares. Attachments

February 18, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch